Severe eczema, also known as atopic dermatitis (AD) and atopic eczema, is a chronic inflammatory autoimmune disease, where the skin barrier can be defective, leading to loss of function which means allergens can sensitise through the skin. It is characterised by itchy, non-contagious, inflamed skin that can be present on any part of the body.
Despite affecting approximately 1.5 million adults (3%) in the UK, it is significantly under prioritised by policy makers and the NHS. This has led to significant challenges in the diagnosis, treatment and management of the condition in adults. This report seeks to raise awareness of the condition and to highlight the significant burden it has on patients, the NHS and the wider UK economy.
This report was written and funded by Sanofi Genzyme, working in collaboration with Allergy UK. The content was approved by Allergy UK and reviewed by Sanofi Genzyme to ensure compliance with the ABPI Code of Practice.